FindTrial
Sign In

The value of random biopsy during repeated transurethral in middle and high risk non muscle invasive bladder cancer

The value of random biopsy during repeated transurethral in middle and high risk non muscle invasive bladder cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049471
Enrollment
Unknown
Registered
2021-08-02
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bladder cancer

Interventions

Experimental group:random biopsy
Control Group:selective biopsy

Sponsors

Shanghai Minhang Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 8 Years

Inclusion criteria

Inclusion criteria: 1. Sign the informed consent; 2. Aged 18 to 85 years; 3. Intermediate and high-risk non-muscle invasive bladder cancer, in line with the indications for secondary resection of bladder cancer, agree to undergo secondary resection; 4. Positive secondary resection, refusal or intolerant of radical cystectomy.

Exclusion criteria

Exclusion criteria: 1. Low-risk non-muscle-invasive bladder cancer, or muscle-invasive bladder cancer; 2. Severe systemic disease, unable to tolerate general anesthesia; 3. Severe bleeding tendency or coagulation dysfunction.

Design outcomes

Primary

MeasureTime frame
finding rate;—

Countries

China

Contacts

Public ContactLu Xuwei

Shanghai Minhang Hospital, Fudan University

luxuwei_1108@live.com+86 18117370696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026